This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegall, C. B. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Siegall, C. B. Articles by Pastan, I.

Expression of the Interleukin 6 Receptor and Interleukin 6 in Prostate Carcinoma Cells

Laboratory of Molecular Biology, Division of Cancer Biology and Diagnosis and Centers [C. B. S., D. J. F., I. P.], and Medicine Branch, Division of Cancer Treatment [G. S., R. P. N.], National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

We have probed for the presence of interleukin 6 (IL6) receptors in prostatic carcinoma cell lines (LNCaP, DU 145, and PC3) by examining their sensitivity to the cytotoxic effects of a chimeric toxin composed of IL6 and Pseudomonas exotoxin (PE). All three cell lines were killed by IL6-PE66^4Glu, a version of IL6-PE in which the binding domain of native PE has been mutated to debilitate PE binding to its own receptor. This cytotoxic activity confirmed the presence of IL6 receptors on prostatic carcinoma cells. We have measured the number of IL6 receptors found on these cells and have further determined that they secrete IL6. These data provide evidence that IL6 and its receptor may play an important role in human prostate cancer.

Received 7/ 9/90. Accepted 9/10/90.

This article has been cited by other articles:

				M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]

				C. N. Papandreou, D. D. Daliani, D. Nix, H. Yang, T. Madden, X. Wang, C. S. Pien, R. E. Millikan, S.-M. Tu, L. Pagliaro, et al. Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer J. Clin. Oncol., June 1, 2004; 22(11): 2108 - 2121. [Abstract] [Full Text] [PDF]

				S. O. Lee, W. Lou, M. Hou, F. de Miguel, L. Gerber, and A. C. Gao Interleukin-6 Promotes Androgen-independent Growth in LNCaP Human Prostate Cancer Cells Clin. Cancer Res., January 1, 2003; 9(1): 370 - 376. [Abstract] [Full Text] [PDF]

				L. B. Mora, R. Buettner, J. Seigne, J. Diaz, N. Ahmad, R. Garcia, T. Bowman, R. Falcone, R. Fairclough, A. Cantor, et al. Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells Cancer Res., November 15, 2002; 62(22): 6659 - 6666. [Abstract] [Full Text] [PDF]

				T. Ueda, N. Bruchovsky, and M. D. Sadar Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways J. Biol. Chem., February 22, 2002; 277(9): 7076 - 7085. [Abstract] [Full Text] [PDF]

				T. Chen, L. H. Wang, and W. L. Farrar Interleukin 6 Activates Androgen Receptor-mediated Gene Expression through a Signal Transducer and Activator of Transcription 3-dependent Pathway in LNCaP Prostate Cancer Cells Cancer Res., April 1, 2000; 60(8): 2132 - 2135. [Abstract] [Full Text]

				E. Levesque, M. Beaulieu, C. Guillemette, D. W. Hum, and A. Belanger Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line Endocrinology, May 1, 1998; 139(5): 2375 - 2381. [Abstract] [Full Text] [PDF]

				Y. Qiu, D. Robinson, T. G. Pretlow, and H.-J. Kung Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells PNAS, March 31, 1998; 95(7): 3644 - 3649. [Abstract] [Full Text] [PDF]

				E. T. Keller, C. Chang, and W. B. Ershler Inhibition of NFkappa B Activity through Maintenance of Ikappa Balpha Levels Contributes to Dihydrotestosterone-mediated Repression of the Interleukin-6 Promoter J. Biol. Chem., October 18, 1996; 271(42): 26267 - 26275. [Abstract] [Full Text] [PDF]